p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas

Laboratory Investigation

Volumn 74, Issue 1, 1996, Pages 279-289

  Weyrer, Katharina ^a,b   Feichtinger, Hans ^a,b   Haun, Margot ^a,b   Weiss, Günter ^a,b   Öfner, Dietmar ^a,b   Weger, Adolf R ^c   Umlauft, Florian ^a,b   Grünewald, Kurt ^a,b  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER GENETICS; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PLOIDY; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; AGED; BASE SEQUENCE; CARCINOMA, DUCTAL, BREAST; DNA, NEOPLASM; FEMALE; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PANCREATIC NEOPLASMS; PLOIDIES;

EID: 0030048977     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. American Joint Committee for cancer staging and end-results reporting (1977). In: American Joint Committee on cancer. Manual for staging of cancer. Chicago, 85-88.
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, and Perucho M (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
3. Barton CM, Staddon SL, Huges CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Russel RCG, Neotolemos J, Williamson RCN, Lane DP, and Lemoine NR (1991). Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076-1082.
4. Berrozpe G, Schaeffer J, Peinado MA, Real FX, and Perucho M (1994). Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58:185-191.
5. Carbone D, Chiba I, and Mitsudomi T (1991). Polymorphism at codon 213 within the p53 gene. Oncogene 6:1691-1692.
6. Carder PJ, Wyllie AH, Purdie CA, Morris RG, White S, Pris J, and Bird CC (1993). Stabilized p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8:1397-1401.
7. Caron de Formentel and Soussi T (1992). TP53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosomes & Cancer 4:1-15.
8. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, Berger HG, and Korc M (1993). p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 69:151-160.
9. Coulondre C, Miller JH, Farabaugh PJ, and Gilbert W (1978). Molecular basis of base substitution hot spots in Escherichia coli. Nature 274:775-780.
10. DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC, Cameron JL, and Offerhaus GJ (1994). Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 101:684-688.
11. Eliyahu D, Raz A, Gruss P, Givol D, and Oren M (1984). Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646-649.
12. Goh HS, Chan CS, Khine K, and Smith DR (1994). p53 and behaviour of colorectal cancer. Lancet 344:233-234.
13. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, and Bartram CR (1989). High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43:1037-1041.
14. Grünewald K, Lyons J, Hansen-Hagge TE, Janssen JWG, Feichtinger H, and Bartram CR (1991). Molecular genetic analysis of DNA obtained from fixed, air dried or paraffin embedded sources. Ann Hematol 62:108-114.
15. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, and Lemoine NR (1990). The c-erB-2 proto-oncogene in human pancreatic cancer. J Pathol 161:195-200.
16. Hinds P, Finlay C, and Levine AJ (1989). Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739-746.
17. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancers. Science 253:49-53.
18. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, and Harris CC (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucl Acid Res 22:3551-3555.
19. Jego N, Thomas G, and Hamelin R (1993). Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene 8:209-213.
20. Kalbfleisch JD and Prentice RL (1980). The statistical analysis of failure data time. New York: John Wiley and Sons.
21. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H, and Deppert W (1993). p53 and k-ras alterations in pancreatic epithelial cell lesions. Oncogene 8:289-298.
22. Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481.
23. Kloeppel G (1984). Pancreatic, non-endocrine tumors. In: Kloeppel G and Heitz PU, editors. Pancreatic pathology. Edinburgh: Churchill Livingstone, 79-113.
24. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchler M, and Berger GB (1992). Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352-1360.
25. Kroft SH and Oyasu R (1994). Urinary bladder cancer: Mechanisms of development and progression. Lab Invest 72:158-174.
26. Lane DP (1992). Cancer: p53, guardian of the genome. Nature 358:15-16.
27. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, and Welsh D (1994). The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69:409-416.
28. Lindahl T (1993). Instability and decay of the primary structure of DNA. Nature 362:709-715.
29. Oliner J (1994). The role of p53 in cancer development. Scientific Am Sci Med September/October:16-25.
30. Orita M, Suzuki Y, Sekiya T, and Hayashi K (1989). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879.
31. Parada LF, Land H, Weinberg RA, Wolf D, and Rotter V (1984). Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312:649-651.
32. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, and Ranzani GN (1994). K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54: 1556-1560.
33. Poston GJ, Gillespie J, and Guillou PJ (1991). Biology of pancreatic cancer. Gut 32:800-812.
34. Raycroft L, Wu H, and Lozano G (1990). Transcriptional activation by wildtype but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051.
35. Redstone MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, and Kern SE (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54: 3025-3033.
36. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, and Klein-Szanto AJP (1992a). Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7:1503-1511.
37. Ruggeri B, Zhang SY, and Klein-Szanto AJP (1992b). Molecular and cytogenetic alterations in human pancreatic cancer: The role of tumor suppressor genes. In: Comparative Molecular Carcinogenesis. New York: Wiley-Liss, Inc, 245-260.
38. Scarpa A, Capelli P, Mukai K, Zamboni G, Tatsuya O, Iacono C, and Hirohashi S (1993). Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142:1534-1543.
39. Scarpa A, Capelli P, Villanueva A, Zamboni G, Lluís F, Accolla R, Mariuzzi G, and Capellà G (1994). Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int J Cancer 57:167-171.
40. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, and Stone EM (1993). The sensitivity of single-strand-conformation polymorphism analysis for the detection of single base substitutions. Genomics 16:325-332.
41. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, and Bos JL (1988). KRAS codon 12 mutation occur very frequently in pancreatic adenocarcinomas. Nucl Acids Res 16:7773-7782.
42. Sommer SS, Cunninham J, McGovern RM, Saitoh S, Schroeder JJ, Wold LE, and Kovach JS (1992). Pattern of p53 gene mutations in breast cancers of woman of the Midwestern United States. J Natl Cancer Inst 84:246-252.
43. Soto D and Sukumar S (1992). Improved detection of mutations in the p53 gene in human tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA. PCR Meth Appl 2:96-98.
44. Soussi T, Legros Y, Lubin R, Ory K, and Schlichtholz B (1994). Mulitfactorial analysis of p53 alterations in human cancer: A review. Int J Cancer 57:1-9.
45. Suzuki Y, Sekiya T, and Hayashi K (1991). Allele-specific polymerase chain reaction: A method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal Biochem 192:82-84.
46. Weger AR, Askensten U, Schwab G, Glaser KS, Auer GU, and Mikuz G (1989). Methodological aspects on DNA image cytometry in formalin-fixed paraffin-embedded material from pancreatic adenocarcinoma. Pathol Res Pract 185:752-754.
47. Weger RA, Falkmer US, Schwab G, Glaser KS, Kemmler G, Bodner E, Auer G, and Mikuz G (1990). Nuclear DNA distribution pattern of the parenchymal cells in adenocarcinoma of the pancreas and in chronic pancreatitis. A study of archival specimens using both image and flow-cytometry. Gastroenterology 99:237-242.